Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 14/20 | 0.46 |
| ▸ | NPY1R | P25929 | 9/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.46 |
| ▸ | NPY2R | P49146 | 5/20 | 0.46 |
| ▸ | CTSL | P07711 | 3/20 | 0.43 |
| ▸ | CTSS | P25774 | 3/20 | 0.43 |
| ▸ | CTSK | P43235 | 3/20 | 0.43 |
| ▸ | CTSH | P09668 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29889197 | 0.90 | NPY4R (0.49) | NPY4RNPY1RNPY5RNPY2RCTSL | |
| SCHEMBL30475882 | 0.89 | NPY4R (0.49) | NPY4RNPY1RNPY5RNPY2RPTPN1 | |
| SCHEMBL29476637 | 0.88 | NPY4R (0.45) | NPY4RNPY1RNPY5RNPY2RPTPN1 | |
| SCHEMBL31538114 | 0.88 | NPY4R (0.42) | NPY4RNPY1RNPY5RNPY2RCTSL | |
| SCHEMBL30866245 | 0.88 | NPY4R (0.42) | NPY4RNPY1RNPY5RNPY2RCTSL | |
| SCHEMBL30656923 | 0.88 | NPY4R (0.57) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29387939 | 0.88 | PTPN1 (0.48) | NPY4RNPY1RNPY5RCTSLCTSS | |
| SCHEMBL30543172 | 0.87 | NPY4R (0.47) | NPY4RNPY1RNPY5RNPY2RCTSL | |
| SCHEMBL29630328 | 0.87 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2RCTSL | |
| SCHEMBL30475880 | 0.86 | NPY4R (0.49) | NPY4RNPY1RNPY5RNPY2RCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212549-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212549-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | FIBP, FN1, TPX2 | NPY4R 199/4885NPY1R 160/4885NPY5R 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.